---
layout: default
title: Ranolazine
parent: 僅模型預測 (L5)
nav_order: 89
evidence_level: L5
indication_count: 1
---

# Ranolazine
{: .fs-9 }

證據等級: **L5** | 預測適應症: **1** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ranolazine: Repurposing Evaluation Incomplete — Insufficient Evidence Pack Data

## One-Sentence Summary

Ranolazine (DrugBank ID: DB00243) is a cardiovascular drug with no current Taiwan regulatory approval.
The TxGNN model has **not generated any repurposing predictions** for this candidate,
and two critical data gaps — including a **Blocking-severity** absence of TFDA safety data and **High-severity** absence of mechanism of action — prevent a complete evaluation at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available (no Taiwan license on record) |
| Predicted New Indication | None — TxGNN predictions not generated |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 (no predictions or studies available) |
| Taiwan Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN repurposing prediction has been generated for Ranolazine in this Evidence Pack. Without a predicted indication, a mechanistic rationale cannot be constructed.

The mechanism of action (MOA) is flagged as a **High-severity data gap (DG002)**. Without knowing how Ranolazine exerts its therapeutic effect, it is not possible to reason about which other disease pathways it might engage. The DrugBank API query recorded in the query log (ID: 3) returned a result, but MOA content was not populated into the Evidence Pack — this should be resolved by re-parsing the DrugBank response.

The TFDA package insert query (query log ID: 4) also returned a result, yet no approved indications, warnings, or contraindications were extracted into the Evidence Pack. Until these two remediation steps are completed, mechanistic analysis is blocked.

---

## Taiwan Market Information

Ranolazine has no approved drug licenses in Taiwan. No authorization records are available for review.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Data Gap Notice:** Key warnings, contraindications, and drug-drug interaction data are all unavailable in this Evidence Pack. Notably, a **Blocking-severity data gap (DG001)** exists for TFDA package insert warnings and contraindications — this prevents entry into the S1 safety pre-screening phase. The DDI query (query log ID: 2) returned `not_found`.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This candidate cannot be evaluated for repurposing at this time. The absence of TxGNN predictions, missing MOA, and unresolved Blocking-severity safety data gap collectively prevent any meaningful assessment of benefit, risk, or mechanistic plausibility.

**To proceed, the following is needed:**

- **[DG001 — Blocking]** Re-parse the TFDA package insert PDF (query already succeeded; extraction pipeline needs review) to populate warnings and contraindications
- **[DG002 — High]** Re-query DrugBank API and extract MOA, drug categories, and toxicity fields for Ranolazine (DB00243)
- **Re-run TxGNN pipeline** after MOA and indication data are populated, to generate repurposing predictions
- **Re-run DDI query** against an alternative source (e.g., DrugBank interaction endpoint) to populate drug interaction data
- Once predictions are available, re-generate this Evidence Pack at v5+ for full evaluation
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

